|Type||Buy / Hold / Sell|
|Year End 31st Dec||Unit||2018||2019||2020||2021||2022||2023E||2024E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
- 2476 Argentia Road, Suite 402, MISSISSAUGA, L5N 6M1
- +1 9052060013
- MNP LLP
Upcoming Events for RX
Biosyent Inc Annual Shareholders Meeting
Q1 2024 Biosyent Inc Earnings Release
As of Today at 18:04 UTC, shares in Biosyent are trading at CA$8.64. This share price information is delayed by 15 minutes.
Shares in Biosyent last closed at CA$8.64 and the price had moved by +17.1% over the past 365 days. In terms of relative price strength the Biosyent share price has outperformed the Toronto Stock Exchange 300 Composite Index by +17.29% over the past year.
The overall consensus recommendation for Biosyent is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Biosyent dividend yield is 1.85% based on the trailing twelve month period.
Last year, Biosyent paid a total dividend of CA$0.16, and it currently has a trailing dividend yield of 1.85%.Looking ahead, the next dividend pay date is 2023-12-15.
We do not have data on when Biosyent is to next pay dividends. The historic dividend yield on Biosyent shares is currently 1.85%.
To buy shares in Biosyent you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$8.64, shares in Biosyent had a market capitalisation of CA$102.14m.
Here are the trading details for Biosyent:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: RX
Based on an overall assessment of its quality, value and momentum Biosyent is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biosyent is CA$9.00. That is 4.17% above the last closing price of CA$8.64.
Analysts covering Biosyent currently have a consensus Earnings Per Share (EPS) forecast of CA$0.21 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biosyent. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +11.06%.
As of the last closing price of CA$8.64, shares in Biosyent were trading +13.06% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biosyent PE ratio based on its reported earnings over the past 12 months is 23.57. The shares last closed at CA$8.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biosyent's management team is headed by:
- Rene Goehrum - CHM
- Robert March - CFO
- Joost van der Mark - VPR
- Kevin Wilson - VPR
- Peter Lockhard - LED
- Navid Ashrafi - DRC
- Sharan Raghubir - DRC
- Larry Andrews - IND
- Joseph Arcuri - IND
- Sara Elford - IND
- Stephen Wilton - IND